• Seliukova N. Yu. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine; National Pharmaceutical University, Kharkiv, Ukraine
  • Misiura K. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine



fetoplacental insufficiency, placenta, pharmacological correction of pregnant, progesterone, estriol


The review of the literature is devoted to the hormonal regulation of one of the transitional organs — the
placenta. The placenta is a multifunctional organ that ensures optimal growth of the fetus and its functioning.
In dysfunction of the fetoplacental complex (FPC), so-called fetoplacental insufficiency (FPI) can develop, which
lead to disorders of hemodynamic, transport, respiratory, metabolic and endocrine function of the placenta.
The main function of the placenta is the ability to synthesize important hormones and mediators. The clinic
uses indicators of the level of placental hormones to diagnose a particular disease in the fetus. The function of
FPC is characterized by the concentration of estriol, since the suffering of the fetus due to FPI, the production
of this hormone by his liver decreases. The state of the placenta during the second half of pregnancy is most
characterized by the level of progesterone in the blood, the level of the latter is also significantly reduced, which
occurs against the background of impaired maturation of the placenta.
It is known that women with a very young and mature reproductive age are at high risk of developing
ESRD. The use of medications during pregnancy is progressively increasing, with more and more pregnant
women requiring pharmacotherapy. That is why in our research we decided to study and compare progeste­ rone and estriol depending on the mother’s age. At the State Institution «V. Danilevsky Institute for Endocrine
Pathology Problems of the NAMS of Ukraine» we conducted a comprehensive experimental study on this issue.
To solve this problem, a new pharmaceutical composition has been developed and offered at our institute,
which should contribute not only to the correction of FPI but also to preventive value in preserving the reproductive potential in adulthood. Wistar rats of two age groups were used for this purpose. The experimental FPI
was simulated, afterwards, the correction by the pharmaceutical composition was performed.
Our research has allowed us to establish that FPI has different effects on females of different age groups.
It has been experimentally demonstrated that in pregnant women of young reproductive age there is a significant decrease in progesterone and estriol levels in the presence of FPI. In mature animals whose pregnancy is
complicated by FPI, progesterone and estriol levels, which are almost indistinguishable from the intact group
of animals, are observed, which may indicate the initiation of compensatory adaptive reactions of the organism. Developed at the State Institution «V.Danilevsky Institute for Endocrine Pathology Problems of the
NAMS of Ukraine» pharmaceutical composition normalizes progesterone and estriol levels in rats of young
reproductive age against FPI


Demografichna sytuacija v Ukrai’ni u sichni–travni 2019 roku, available at: ua/PXWEB2007/ukr/publ_new1/2019/dem_0519.pdf.

Koval’chuk AJu. Ukr Med Chasopys 2014; 1(99): 29-33.

Ustinov OV. Sluhannja z problem reproduktyvnogo zdorov’ja, available at:, 2015.

Owens JA. Reprod Fertil Dev 1991; 3(5): 501-517.

Burton GJ, Jauniaux E. Am J Obstet Gynecol 2018; 218(2S): S745-S761. doi:

Sankaran S, Kyle PM. Best Pract Res Clin Obstet Gynaecol 2009; 23: 765-777. doi: 05.003.

Ghidini A. Obstet Gynecol Surv 1996; 51(6): 376-382.

Figueras F, Gratacos E. Best Pract Res Clin Obstet Gynaecol 2017; 38: 48-58. doi: 10.006.

Giussani DA. J Physiol 2016; 594: 1215-1230. doi: 10.1113/JP271099.

Ji L, Brkic J, Liu M, et al. Mol Aspects Med 2013; 34: 981-1023. doi: 10.1016/j.mam.2012.12.008.

Handschuh K, Guibourdenche J, Tsatsaris V, et al. Placenta 2007; 28: 175-184. doi: 01.019.

Bonduelle ML, Dodd R, Liebaers I, et al. Hum Reprod 1988; 3: 909-914.

Barnea ER, Kaplan M. J Clin Endocrinol Metab 1989; 69: 215-217.

Cole LA. Reprod Biol Endocrinol 2012; 10: 24. doi: 10.1186/1477-7827-10-24.

Toth P, Li X, Rao CV, et al. J Clin Endocrinol Metab 1994; 79: 307-315.

Schumacher A, Brachwitz N, Sohr S, et al. J Immunol 2009; 182: 5488-5497. doi:

Slattery MM, Brennan C, O’Leary MJ, Morrison JJ. BJOG 2001; 108: 704-708. doi: 139345.

Abdel Moety GA, Almohamady M, Sherif NA, et al. J Matern Fetal Neonatal Med 2015: 1-5. doi:

Spencer K, Yu CK, Cowans NJ, et al. Prenat Diagn 2005; 25: 949-953. doi:

Androutsopoulos G, Gkogkos P, Decavalas G. Int J Endocrinol Metab 2013; 11: 102-106. doi:

Shabalov NP, Cveleva JuV. Osnovy perinatologii, Moskva, 2004.

Costa MA. Reprod Biomed Online 2016; 32(1): 14-43. doi: 10.1016/j.rbmo.2015.10.005.

Tarrade A, Lai Kuen R, Malassine A, et al. Lab Invest 2001; 81: 1199-1211.

Michael Freemark. J Clin Endocrinol Metab 2010; 95(5): 2054-2057. doi: 10.1210/jc.2010-0517.

Tuckey RC. Placenta 2005; 26: 273-281. doi: placenta.2004.06.012.

Sugawara T, Holt JA, Driscoll D, et al. Proc Natl Acad Sci USA 1995; 92: 4778-4782.

Brar AK, Frank GR, Kessler CA, et al. Endocrine 1997; 6: 301-307.

Halasz M, Szekeres-Bartho J. J Reprod Immunol 2013; 97: 43-50. doi:

Ruddock NK, Shi SQ, Jain S, et al. Am J Obstet Gynecol 2008; 199: e391-e397. doi:

Coya R, Martul P, Algorta J, et al. Gynecol Endocrinol 2005; 21: 27-32. doi: 10.1080/09513590500099305.

Lappas M, Yee K, Permezel M, Rice GE. J Endocrinol 2005; 186: 457-465. doi: 10.1677/joe.1.06227.

Pang WW, Hartmann PE. J Mammary Gland Biol Neoplasia 2007; 12: 211-221. doi: 10.1007/s10911-007-9054-4.

Butte NF. Am J Clin Nutr 2000; 71: 1256S-1261S. doi:

Shanker YG, Rao AJ. Biochem Mol Biol Int 1997; 43: 591-599.

Nestler JE. Endocrinology 1989; 125: 2127-2133.

Barrera D, Avila E, Hernandez G, et al. J Steroid Biochem Mol Biol 2007; 103: 529-532. doi: 2006.12.097.

Cameo P, Bischof P, Calvo JC. Biol Reprod 2003;68: 472-477. doi:

Gao L, Tao Y, Hu T, et al. Endocrinology 2012; 153: 4918-4928. doi: 10.1152/physrev.00043.2017.

Goshovs’ka AV, Byrchak IV, Goshovs’kyj VM. Bukovyn Med Vistn 2016; 20(3): 49-52.

Bjornstrom L, Sjoberg M. Mol Endocrinol 2005; 19: 833-842. doi:

Bechi N, Ietta F, Romagnoli R, et al. Toxicol Sci 2006; 93: 75-81. doi: 10.1093/toxsci/kfl043.

Di WL, Lachelin GC, McGarrigle HH, et al. Mol Hum Reprod 2001; 7: 671-679.

Holinka CF, Diczfalusy E, Coelingh Bennink HJ. J Steroid Biochem Mol Biol 2008; 110: 138-143. doi: 10.1016/j. jsbmb.2008.03.027.

Groothuis PG, Dassen HH, Romano A, Punyadeera C. Hum Reprod Update 2007; 13: 405-417. doi:

Punyadeera C, Dassen H, Klomp J, et al. Cell Mol Life Sci 2005; 62: 239-250.

Corcoran JJ, Nicholson C, Sweeney M, et al. Mol Hum Reprod 2014; 20: 433-441. doi: 10.1093/molehr/gat095.

Bukovsky A, Cekanova M, Caudle MR, et al. Reprod Biol Endocrinol 2003; 1: 13.

Gambino YP, Maymo JL, Perez-Perez A, et al. Biol Reprod 2010; 83: 42-51. doi: 10.1095/biolreprod.110. 083535.

Pang WW, Hartmann PE. J Mammary Gland Biol Neoplasia 2007; 12: 211-221. doi: 10.1007/s10911-007-9054-4.

Butte NF. Am J Clin Nutr 2000; 71: 1256S-1261S. doi: 10.1093/ajcn/71.5.1256s.

Wang WS, Liu C, Li WJ, et al. Placenta 2014; 35: 30-36. doi:

Kumar P, Kamat A, Mendelson CR. Mol Endocrinol 2009; 23: 784-793. doi: 10.1210/me.2008-0371.

Coya R, Martul P, Algorta J, et al. Gynecol Endocrinol 2006; 22: 620-626. doi:

Mucci LA, Lagiou P, Tamimi RM, et al. Cancer Causes Control 14: 311-318.

Mucci LA, Lagiou P, Hsieh CC, et al. BJOG 2004; 111:989-995. doi:

Kirkegaard I, Henriksen TB, Uldbjerg N. Ultrasound Obstet Gynecol 2011; 37: 341-347.

Odibo AO, Zhong Y, Longtine M, et al. Placenta 2011; 32: 333-338. doi:

Chafetz I, Kuhnreich I, Sammar M, et al. Am J Obstet Gynecol 2007; 197: e31-e37. doi: 10.1016/j.ajog.2007. 02.025.

Than NG, Balogh A, Romero R, et al. Front Immunol 2014; 5: 348. doi:

Kyriakakou M, Malamitsi-Puchner A, Militsi H, et al. Eur J Endocrinol 2008; 158: 343-348. doi:

Savvidou MD, Sotiriadis A, Kaihura C, et al. Clin Sci (Lond.) 2008; 115: 219-224. doi: 10.1042/CS20070409.

Fasshauer M, Bluher M, Stumvoll M, et al. Clin Endocrinol (Oxf) 2007; 66: 434-439. doi: 2007.02751.x.

Agrogiannis GD, Sifakis S, Patsouris ES, Konstantinidou AE. Mol Med Reports 2014; 10: 579-584. doi:

Netchine I, Azzi S, Le Bouc Y, Savage MO. Best Pract Res Clin Endocrinol Metab 2011; 25: 181-190. doi: 1016/j.beem.2010.08.005.

Gorbach TV, Denisenko SA, Martynova SN, Gopkalov VG. Funkcional’naja biohimija sistemy mat’–placenta–plod: metod. ukaz. dlja studentov II kursa med. fakul’teta, Har’kov, 2013: 64 p.

Krasnopol’skij VI, Logutova LS, Petruhin VA. Ros Vestn akush-ginek 2008; 2: 87-95.

Murashko LE. Placentarnaja nedostatochnost’. Aktual’­ nыe voprosы patologyy rodov, ploda, novorozhdennogo: Posobye dlja vrachej, Moskva, 2003: 38-45.

Abramchenko VV, Shabalov NP. Klynycheskaja perynatologyja, Petrozavodsk, 2004.

Lіhachov VK, Petrenko JuV. Problemy, dostizhenija i perspektivy mediko-biologicheskih nauk i prakticheskogo zdravoohranenija, Simferopol’, 2009; 145(3): 151-155.

Patel R, Moffatt JD, Mourmoura E, et al. J Physiol 2017; 595(6): 2065-2084. doi: 10.1113/JP273350.

Jakovlєva LV, Zajchenko GV, Cipkun AG, et al. Doklіnіchne vivchennja lіkars’kih zasobіv, priznachenih dlja lіkuvannja placentarnoї disfunkcії: metod. Rekomendacії, Kiїv, 2009.

Kocabin NV, Makarchuk OM. Zdorov’e Zhenshhiny 2015; 5(101): 150-153.

Settiyanan T, Wanapirak C, Sirichotiyakul S, et al. J Matern Fetal Neonatal Med. 2016; 29(13): 2093-2097. doi:

Bagot CN, Leishman E, Onyiaodike CC, et al. Thromb Res 2019; 178: 47-53. doi: 10.1016/j.thromres.2019.03.015.




How to Cite

Seliukova, N. Y., & Misiura, K. V. (2019). PECULIARITIES OF THE ENDOCRINAL FUNCTION OF PL ACENTA OF FEMALES OF DIFFERENT AGE WITH FETOPLACENTAL FAILURE (literature review and own research). Problems of Endocrine Pathology, 70(4), 130-141.

Most read articles by the same author(s)

1 2 > >>